{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling in tumors.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) 3.1 vs 1.0 Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination broadens the peptide repertoire presented on MHC-I, improving tumor visibility to T cells.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3% Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C03",
      "claim": "Combined intratumoral mRNA vaccination and anti-PD-L1 therapy improves tumor control in mice.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x Increased immune infiltration with combination therapy",
          "line_ref": "L33"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination correlates with better outcomes in patients receiving immune checkpoint inhibitors.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value p=0.01 N/A Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C05",
      "claim": "PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue 2.4x vs 1.0x Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    }
  ]
}